PMID- 33165709
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 185
IP  - 3
DP  - 2021 Feb
TI  - Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response 
      and prognostication of event-free survival in HER2-positive and biopsy-proven 
      node-positive breast cancer treated with neoadjuvant therapy.
PG  - 629-638
LID - 10.1007/s10549-020-06015-4 [doi]
AB  - PURPOSE: The present study evaluated tumor-infiltrating lymphocytes (TILs) based 
      on standardized scoring method and investigated its predictive value for axillary 
      pathologic complete response (apCR) and prognostic significance for event-free 
      survival (EFS) in neoadjuvant-treated HER2-positive breast cancer with initially 
      biopsy-proven nodal metastasis. METHODS: We assessed TILs in a total of 187 
      pretherapeutic core biopsies of primary tumors. Receiver operating characteristic 
      curve analysis was conducted to calculate the optimal cut-off point of TILs in 
      discriminating axillary pathologic response. The associations of TILs with apCR 
      or EFS were investigated by univariate and multivariate analyses. RESULTS: 
      Receiver operating characteristic curve analysis identified a 10% cut-off point 
      of TILs that optimally discriminated apCR from non-apCR (P < 0.001). High TILs 
      were determined as TILs >/= 10%, and tumor with TILs < 10% was defined as 
      lymphocyte-depleted breast cancer (LDBC). The apCR rate of the entire cohort was 
      66.3% (124/187). Tumors with high TILs had a significantly higher apCR rate 
      compared with LDBC (78.5% vs. 43.9%; P < 0.001). High TILs (P < 0.001), breast 
      pathologic complete response (P = 0.006), and negative status of hormone receptor 
      (P = 0.021) were independent predictors for apCR. High TILs were a markedly 
      powerful predictor with an odds ratio of 4.01 (P < 0.001). EFS was significantly 
      better among patients with high TILs than among those with LDBC (P < 0.001). 
      Univariate and multivariate analyses indicated that high TILs (P = 0.019) and 
      apCR (P = 0.013) were independent predictors for favorable EFS. CONCLUSIONS: TILs 
      have predictive value for apCR and prognostic significance for EFS in initially 
      node-positive and HER2-positive breast cancer treated with neoadjuvant therapy. 
      LDBC (TILs < 10%) has a significantly unfavorable impact on apCR rate and EFS.
FAU - Liu, Shiwei
AU  - Liu S
AD  - Department of Breast Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer 
      Center, School of Medicine, University of Electronic Science and Technology of 
      China, Chengdu, 610000, China.
FAU - Zeng, Shiyan
AU  - Zeng S
AD  - Department of Breast Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer 
      Center, School of Medicine, University of Electronic Science and Technology of 
      China, Chengdu, 610000, China.
FAU - Xia, Li
AU  - Xia L
AD  - Department of Breast Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer 
      Center, School of Medicine, University of Electronic Science and Technology of 
      China, Chengdu, 610000, China.
FAU - Yu, Miao
AU  - Yu M
AD  - Department of Breast Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer 
      Center, School of Medicine, University of Electronic Science and Technology of 
      China, Chengdu, 610000, China.
FAU - Zhang, Xin
AU  - Zhang X
AD  - Department of Breast Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer 
      Center, School of Medicine, University of Electronic Science and Technology of 
      China, Chengdu, 610000, China.
FAU - Yang, Hong
AU  - Yang H
AD  - Department of Pathology, Sichuan Cancer Hospital & Institute, Sichuan Cancer 
      Center, School of Medicine, University of Electronic Science and Technology of 
      China, Chengdu, 610000, China.
FAU - Ji, Juan
AU  - Ji J
AD  - Department of Pathology, Sichuan Cancer Hospital & Institute, Sichuan Cancer 
      Center, School of Medicine, University of Electronic Science and Technology of 
      China, Chengdu, 610000, China.
FAU - Dong, Hao
AU  - Dong H
AD  - Department of Pathology, Sichuan Cancer Hospital & Institute, Sichuan Cancer 
      Center, School of Medicine, University of Electronic Science and Technology of 
      China, Chengdu, 610000, China.
FAU - Zhang, Jianhui
AU  - Zhang J
AD  - Department of Breast Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer 
      Center, School of Medicine, University of Electronic Science and Technology of 
      China, Chengdu, 610000, China.
FAU - Zhang, Purong
AU  - Zhang P
AUID- ORCID: 0000-0003-4317-1355
AD  - Department of Breast Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer 
      Center, School of Medicine, University of Electronic Science and Technology of 
      China, Chengdu, 610000, China. PurongZhang@outlook.com.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Biopsy
MH  - *Breast Neoplasms/drug therapy
MH  - Female
MH  - Humans
MH  - Lymphocytes, Tumor-Infiltrating
MH  - *Neoadjuvant Therapy
MH  - Prognosis
MH  - Progression-Free Survival
MH  - Receptor, ErbB-2/genetics
OTO - NOTNLM
OT  - Axillary pathologic response
OT  - HER2
OT  - Neoadjuvant therapy
OT  - Survival
OT  - Tumor-infiltrating lymphocytes
EDAT- 2020/11/10 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/11/09 14:26
PHST- 2020/02/29 00:00 [received]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/11/09 14:26 [entrez]
AID - 10.1007/s10549-020-06015-4 [pii]
AID - 10.1007/s10549-020-06015-4 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2021 Feb;185(3):629-638. doi: 
      10.1007/s10549-020-06015-4. Epub 2020 Nov 9.